Patents by Inventor John Simard

John Simard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • True human antibody specific for interleukin 1 alpha
    Publication number: 20260132192
    Abstract: Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1? and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.
    Type: Application
    Filed: January 8, 2026
    Publication date: May 14, 2026
    Inventors: John Simard, Sushma Shivaswamy, Galina Kuzmicheva
  • True human antibody specific for interleukin 1 alpha
    Publication number: 20260132193
    Abstract: Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1? and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.
    Type: Application
    Filed: January 8, 2026
    Publication date: May 14, 2026
    Inventors: John Simard, Sushma Shivaswamy, Galina Kuzmicheva
  • True human antibody specific for interleukin 1 alpha
    Publication number: 20260132194
    Abstract: Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1? and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.
    Type: Application
    Filed: January 13, 2026
    Publication date: May 14, 2026
    Inventors: John Simard, Sushma Shivaswamy, Galina Kuzmicheva
  • Herpes Zoster Treatment
    Publication number: 20260125453
    Abstract: Antibodies that target VZV glycoprotein E (gE) bind to recombinant gE with high affinity, bind to gE on the surface of VZV infected cells, interact with immune system effectors (e.g., Fc receptors), mediate antibody-dependent cellular cytotoxicity (ADCC) as well as Antibody Dependent Cellular Phagocytosis (ADCP), and prevent VZV infection of cells.
    Type: Application
    Filed: August 10, 2025
    Publication date: May 7, 2026
    Inventors: John Simard, Sushma Shivaswamy
  • True human antibody specific for interleukin 1 alpha
    Patent number: 12552860
    Abstract: Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1? and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.
    Type: Grant
    Filed: April 3, 2023
    Date of Patent: February 17, 2026
    Assignee: XBIOTECH INC.
    Inventors: John Simard, Sushma Shivaswamy, Galina Kuzmicheva
  • True human antibody specific for interleukin 1 alpha
    Patent number: 12545724
    Abstract: Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1? and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.
    Type: Grant
    Filed: April 3, 2023
    Date of Patent: February 10, 2026
    Assignee: XBIOTECH INC.
    Inventors: John Simard, Sushma Shivaswamy, Galina Kuzmicheva
  • True human antibody specific for interleukin 1 alpha
    Patent number: 12540176
    Abstract: Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1? and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.
    Type: Grant
    Filed: April 3, 2023
    Date of Patent: February 3, 2026
    Assignee: XBIOTECH INC.
    Inventors: John Simard, Sushma Shivaswamy, Galina Kuzmicheva
  • True human antibody specific for interleukin 1 alpha
    Patent number: 12540177
    Abstract: Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1? and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.
    Type: Grant
    Filed: April 3, 2023
    Date of Patent: February 3, 2026
    Assignee: XBIOTECH INC.
    Inventors: John Simard, Sushma Shivaswamy, Galina Kuzmicheva
  • Arthritis Treatment
    Publication number: 20250051436
    Abstract: Administration of a monoclonal Ab (mAb) that specifically targets IL-1? is useful to treating articular and extra-articular symptoms of arthritis.
    Type: Application
    Filed: September 4, 2024
    Publication date: February 13, 2025
    Inventor: John Simard
  • Arthritis treatment
    Patent number: 12116405
    Abstract: Administration of a monoclonal Ab (mAb) that specifically targets IL-1? is useful to treating articular and extra-articular symptoms of arthritis.
    Type: Grant
    Filed: June 21, 2022
    Date of Patent: October 15, 2024
    Assignee: XBIOTECH INC.
    Inventor: John Simard
  • Treatment for neoplastic diseases
    Patent number: 11932688
    Abstract: Administration of a mAb that specifically binds IL-1? is useful for treating tumor-associated diseases in human subjects.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: March 19, 2024
    Assignee: XBiotech Inc.
    Inventor: John Simard
  • HUMAN ANTIBODY SPECIFIC FOR INTERLEUKIN-1ALPHA
    Publication number: 20240034781
    Abstract: Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1? and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.
    Type: Application
    Filed: October 9, 2023
    Publication date: February 1, 2024
    Inventor: John SIMARD
  • Compositions and methods for treating and preventing staphylococcus aureus infections
    Publication number: 20240010711
    Abstract: Methods and compositions for treating a Staphylococcus aureus bloodstream infection in a human subject involve administering to the subject an antibody which specifically binds Staphylococcus aureus protein A (SpA) with a K D of less than 1×10?10 M via its Fab region paratope and is able to mediate opsonization of SpA-expressing Staphylococcus aureus bacteria in the presence of at least 1 mg/ml of IgG immunoglobulins which bind SpA via their Fc regions.
    Type: Application
    Filed: September 11, 2023
    Publication date: January 11, 2024
    Inventor: John Simard
  • Treatment for neoplastic diseases
    Publication number: 20230382989
    Abstract: Administration of a mAb that specifically binds IL-1? is useful for treating tumor-associated diseases in human subjects.
    Type: Application
    Filed: August 11, 2023
    Publication date: November 30, 2023
    Inventor: John SIMARD
  • True human antibody specific for interleukin 1 alpha
    Publication number: 20230322915
    Abstract: Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1? and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.
    Type: Application
    Filed: April 3, 2023
    Publication date: October 12, 2023
    Inventors: John Simard, Sushma Shivaswamy, Galina Kuzmicheva
  • Compositions and methods for treating and preventing infections
    Patent number: 11773157
    Abstract: Antibodies having Fab regions that specifically bind to Staphylococcus aureus protein A are capable of mediating opsinization of Staphylococcus aureus bacteria despite their expression of antibody-neutralizing protein A. These antibodies and antigen-binding fragments thereof can be used in methods of treating and/or preventing Staphylococcus aureus infections.
    Type: Grant
    Filed: April 15, 2022
    Date of Patent: October 3, 2023
    Assignee: XBIOTECH INC.
    Inventor: John Simard
  • True human antibody specific for interleukin 1 alpha
    Publication number: 20230287103
    Abstract: Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1? and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.
    Type: Application
    Filed: April 3, 2023
    Publication date: September 14, 2023
    Inventors: John Simard, Sushma Shivaswamy, Galina Kuzmicheva
  • True human antibody specific for interleukin 1 alpha
    Publication number: 20230287102
    Abstract: Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1? and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.
    Type: Application
    Filed: April 3, 2023
    Publication date: September 14, 2023
    Inventors: John Simard, Sushma Shivaswamy, Galina Kuzmicheva
  • True human antibody specific for interleukin 1 alpha
    Publication number: 20230287104
    Abstract: Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1? and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.
    Type: Application
    Filed: April 3, 2023
    Publication date: September 14, 2023
    Inventors: John Simard, Sushma Shivaswamy, Galina Kuzmicheva
  • TREATMENT OF HIDRADENITIS SUPPURATIVA
    Publication number: 20230235042
    Abstract: Hidradenitis suppurativa can be treated by administering a pharmaceutical composition that includes a pharmaceutically acceptable carrier and a therapeutically effective amount of an agent that selectively binds IL-1?.
    Type: Application
    Filed: April 16, 2021
    Publication date: July 27, 2023
    Inventors: Yanli ZHUANG, Bhaskar SRIVASTAVA, Karen KEEFE, Swaroopa PARATKAR, Bruce RANDAZZO, Emesto MUNOZ, John SIMARD